Introduction
============

Gallstone disease (GD) is the most common disease of the biliary system and the majority of cases are asymptomatic ([@b1-etm-0-0-7291]). The prevalence of GD has grown with the increasing occurrence of unhealthy lifestyles and the obesity epidemic ([@b2-etm-0-0-7291]). Patients with gallstones are characterized by distorted bile acid secretion, which is associated with an increased risk of cardiovascular disease (CVD). Several genetic, metabolic and environmental factors for GD and CVD development have been identified. Environmental CVD risk factors include a sedentary lifestyle, a high-fat diet and cigarette smoking, which in turn have all been associated with GD ([@b3-etm-0-0-7291],[@b4-etm-0-0-7291]). Certain lipid metabolizing genes have been identified as susceptibility genes for GD and CVD in genome-wide association studies or meta-analyses ([@b5-etm-0-0-7291],[@b6-etm-0-0-7291]). Recently, numerous cohort studies have reported an association between GD and CVD ([@b7-etm-0-0-7291]--[@b9-etm-0-0-7291]), while others have revealed no association ([@b7-etm-0-0-7291]). Therefore, a meta-analysis was performed in the present study to better explore the possible associations between CVD and GD.

Materials and methods
=====================

### Data search

Published studies indexed in EMBASE (<http://www.embase.com/>), PubMed (<http://www.ncbi.nlm.nih.gov/pubmed/>) and the Cochrane Library (<http://www.thecochranelibrary.com/>) were systematically searched from their dates of inception to March 3rd, 2018. Search terms included 'carotid' OR 'artery disease' OR 'carotid atherosclerosis' OR 'carotid plaques' OR 'carotid intimal thickness' OR 'carotid artery' OR 'atherosclerosis' OR 'cardiovascular disease' OR 'cerebrovascular disease' AND 'gallstone diseases' OR 'cholelithiasis' OR 'cholecystolithiasis' OR 'stone' OR 'cholecystectomy'. References in the included studies were examined to identify additional studies that were not captured by the initial literature search strategy.

### Study selection

Studies were selected for the meta-analysis based on the following criteria: i) Only cohort studies were included for observational studies; ii) CVD, including coronary heart disease, stroke, coronary artery calcification, aortic atherosclerosis, peripheral artery disease, arterial stiffness and cerebral vascular accident; iii) hazard ratios (HRs), odds ratios (ORs) and 95% confidence intervals (CIs) were either extracted directly from the selected articles or calculated according to the provided data in the studies; and iv) letters, review articles, comments, case reports and systematic reviews were excluded. No language exclusions were applied.

### Data extraction and quality assessment

Two authors (SZ and GS) independently extracted data from the selected studies. Disagreements were resolved by discussion; if this process did not solve a disagreement, a third author (AW) was consulted. The extracted information included authors, publication year, study design, age, sex, with or without CVD in GD group and control, years of follow-up, outcomes, ORs, HRs, confounder adjustment and CIs. The methodological quality of the selected studies was evaluated with the Newcastle-Ottawa Scale ([@b10-etm-0-0-7291]). The scale contained nine points: Comparability (two stars), estimation of outcomes or exposures (three stars) and selection (four stars). Studies that received more than six stars were judged as high quality.

### Statistical analysis and subgroup analysis

STATA version 12.0 (STATA Corp LP, College Station, TX, USA) was used in the present meta-analysis. The combined unadjusted OR and HR were calculated using the random-effects model ([@b11-etm-0-0-7291]). When information was reported for more than one subpopulation (for example, subjects with HRs and unadjusted ORs, subjects from different geographical areas or subjects with different sexes) in one study, each subpopulation was treated as a separate comparison in the meta-analysis. To assess across-study heterogeneity, the inconsistency index (I^2^) was calculated with the significance level set at P\<0.01. A high, moderate and low degree of heterogeneity was assessed using I^2^≥75, I^2^≥50 and I^2^≥25%, respectively. A fixed-effect model for the various studies without heterogeneity was performed. By contrast, the random-effects model was used in the meta-analysis and subgroups to analyze the source of heterogeneity and potential factors. Subgroup analysis was stratified by area, sex, age, years of follow-up, study design and sample size. Between trial heterogeneity was assessed using the χ^2^ test. The effect of each study on the overall estimates was assessed with sensitivity analysis. Direct observation of funnel plots was performed to assess the presence of publication bias and confirmed with an Egger\'s test ([@b12-etm-0-0-7291]).

Results
=======

### Study characteristics

The flowchart of the included studies was presented in [Fig. 1](#f1-etm-0-0-7291){ref-type="fig"}. Overall, 13,833 records were identified through the EMBASE, PubMed and Cochrane Library search. According to the predefined inclusion and exclusion criteria, 10 studies, including retrospective cohort studies (n=7) and prospective cohort studies (n=3) published between 1985 and 2017 were included in the meta-analysis.

In terms of the location, five studies were from Asia ([@b9-etm-0-0-7291],[@b13-etm-0-0-7291]--[@b16-etm-0-0-7291]) and five studies were from Western countries ([@b2-etm-0-0-7291],[@b8-etm-0-0-7291],[@b17-etm-0-0-7291]--[@b19-etm-0-0-7291]). Of the 10 studies included in the meta-analysis, seven reported HRs ([@b2-etm-0-0-7291],[@b8-etm-0-0-7291],[@b9-etm-0-0-7291],13,14,16,17) and eight reported original data, from which unadjusted ORs were calculated ([@b2-etm-0-0-7291],[@b8-etm-0-0-7291],[@b9-etm-0-0-7291],[@b13-etm-0-0-7291]--[@b17-etm-0-0-7291]). Among these studies, there were five prospective cohort studies ([@b2-etm-0-0-7291],[@b9-etm-0-0-7291],[@b15-etm-0-0-7291],[@b17-etm-0-0-7291],[@b18-etm-0-0-7291]) and five retrospective cohort studies ([@b8-etm-0-0-7291],[@b13-etm-0-0-7291],[@b14-etm-0-0-7291],[@b16-etm-0-0-7291],[@b19-etm-0-0-7291]). Cardiovascular diseases and cerebrovascular diseases were studied in nine and two included articles, respectively. For end-point incidence of these studies, two included mortality as an end-point ([@b2-etm-0-0-7291],[@b18-etm-0-0-7291]) and eight studies used morbidity ([@b8-etm-0-0-7291],[@b9-etm-0-0-7291],[@b13-etm-0-0-7291]--[@b17-etm-0-0-7291],[@b19-etm-0-0-7291]). The characteristics of the selected studies were summarized in [Table I](#tI-etm-0-0-7291){ref-type="table"}.

### Main analysis and publication bias

The meta-analysis suggested a significantly increased risk of incidence (HR=1.24, 95% CI: 1.17--1.31; [Fig. 2](#f2-etm-0-0-7291){ref-type="fig"}) and prevalence (unadjusted OR=1.23, 95% CI: 1.21--1.25; [Fig. 3](#f3-etm-0-0-7291){ref-type="fig"}) of CVD with GD, but with substantial heterogeneity \[P\<0.001, I^2^=80.2% (HR); P\<0.001, I^2^=95.8% (unadjusted OR); [Figs. 2](#f2-etm-0-0-7291){ref-type="fig"} and [3](#f3-etm-0-0-7291){ref-type="fig"}\]. Publication bias of the HR was analyzed using the funnel plot, and the results revealed no symmetric distribution of the included studies on both sides of the funnel plot, suggesting a possibility of publication bias ([Fig. 4](#f4-etm-0-0-7291){ref-type="fig"}). No publication bias of HR was identified by Egger\'s test (Pr\>\|z\|=0.679). However, because the number of included studies for unadjusted OR was \<10, the publication bias for it was not assessed. Collectively, it was not certain that the included studies had no publication bias, but there was no evidence to doubt the validity of the results.

### Subgroup analysis

To investigate the influencing factors of heterogeneity, the data were initially stratified by HR and unadjusted OR, then group 1 was further stratified by mean age (HR≥45, unadjusted OR≤60), sex (female), geographical region, follow-up (\<10 years), prospective cohort study and sample size (patients with gallstones\>10,000). Group 2 was stratified by mean age (HR\>45, unadjusted OR\>60), sex (male), geographical region, years of follow-up (≥10 years), retrospective cohort study and sample size (patients with gallstone\>10,000; [Table II](#tII-etm-0-0-7291){ref-type="table"}). The two groups with GD had a risk of CVD; although the risk in group 1 was greater than that of group 2, indicating that the association between GD and CVD was stronger in the younger population or female individuals. The heterogeneity of the HR was significantly reduced in the stratified analysis by years of follow-up and prospective cohorts, indicating that years of follow-up and study design factors may be potential sources of heterogeneity.

Discussion
==========

In the present meta-analysis, it was demonstrated that compared with controls, GD was associated with a 1.24-fold increase in prevalence and a 1.23-fold increase in incidence for CVD, including cardiovascular disease, coronary artery disease and stroke. Previous studies have reached conflicting conclusions about the association between GD and CVD. Several reports have indicated that GD is associated with CVD ([@b8-etm-0-0-7291],[@b9-etm-0-0-7291]), but others have concluded otherwise ([@b7-etm-0-0-7291]). The conflicting findings may be due to differences in the mean age, sex, geographical region, sample size, study design, follow-up and outcome. In the present study, subgroup analysis by mean participant age revealed that young participants had higher CVD risks, suggesting that more attention should be paid to the prevention of CVD in younger patients with GD. It is generally acknowledged that the prevalence of GD in younger individuals is lower than that in older individuals ([@b20-etm-0-0-7291]). Therefore, GD may have a greater impact on CVD risk in populations with a lower prevalence. The effect of GD on CVD was stronger in females in the current meta-analysis, which was consistent with the conclusion of a previous meta-analysis ([@b21-etm-0-0-7291]). Female patients with GD may have more CVD risks, such a pregnancy or oral contraceptive use ([@b22-etm-0-0-7291]). Furthermore, in postmenopausal women, a decrease in high-density lipoprotein (HDL) levels contributes to the development of GD ([@b23-etm-0-0-7291]). Recently, Fan *et al* ([@b21-etm-0-0-7291]) also conducted a meta-analysis on GD and CVD. A notable difference between their study and the present study was that they pooled OR to calculate the risk of CVD ([@b21-etm-0-0-7291]), whereas the current analysis included HR and unadjusted OR, which were pooled separately to calculate the risk of CVD. A previous meta-analysis also separated pooled HR and OR, but did not perform subgroup analysis ([@b24-etm-0-0-7291]).

Various pathogenic mechanisms have been suggested as possible explanations for GD and CVD. Cholesterol accumulation is a major component in atherosclerotic CVD and GD ([@b15-etm-0-0-7291],[@b25-etm-0-0-7291]). These disorders share common risk factors, including age, sex and obesity, as well as lipid and glucose metabolism disorders, which are also key components of metabolic syndrome (MS) ([@b26-etm-0-0-7291],[@b27-etm-0-0-7291]). MS is strongly associated with coronary artery disease, and gallstones may be considered a biliary feature of this syndrome ([@b28-etm-0-0-7291],[@b29-etm-0-0-7291]). It was assumed that patients with GD had a higher risk of having the comorbidities of hypertension, diabetes, coronary arterial disease, atrial fibrillation and hyperlipidemia, all of which have been proved to be conventional risk factors for stroke ([@b16-etm-0-0-7291]). However, Olaiya *et al* ([@b14-etm-0-0-7291]) revealed that GD and diabetes or GD and hyperlipidemia also interacted to increase the stroke risk. Diabetes and hyperlipidemia present the same risks in GD and stroke. Therefore, diabetes or hyperlipidemia with GD may have synergistic effects that can promote strokes. Considering this, checking for GD in patients with diabetes or hyperlipidemia maybe a new strategy for stroke prevention ([@b16-etm-0-0-7291]).

Aberrant inflammation is involved in the development of GD and CVD ([@b30-etm-0-0-7291],[@b31-etm-0-0-7291]). Several inflammatory factors, including von Willebrand factor, lectin-like oxidized low-density-lipoprotein receptor-1, soluble urokinase plasminogen activator receptor, regulated upon activation, normal T-cell expressed and secreted, as well as microparticles, have been proposed as reducing the expression levels of these factors may improve CVD ([@b32-etm-0-0-7291]). The inflammatory process in GD may promote atherosclerosis or vasculopathy in the cerebral vasculature, thereby increasing the risk of CVD. Associated liver diseases, including non-alcoholic fatty liver disease and pyogenic liver abscesses, have been determined to increase the risk of subsequent CVD via a similar mechanism. Inflammation may also be a vascular risk factor in GD ([@b31-etm-0-0-7291]).

Dysbiosis is an alteration in the composition of the gut microbiota, and has been associated with several diseases, including CVD and GD ([@b33-etm-0-0-7291],[@b34-etm-0-0-7291]). Specifically, dysbiosis has been implicated in CVD, with various aspects of cardiometabolic syndrome: Obesity, hypertension, chronic kidney disease and diabetes ([@b35-etm-0-0-7291]). A mechanistic link between gut microbiota formation of trimethylamine-N-oxide (TMAO) and CVD has been repeatedly demonstrated. TMAO has been implicated in atherosclerosis, platelet aggregation, diabetes and hypertension ([@b36-etm-0-0-7291]). Gut and biliary tract dysbiosis disequilibrates the enterohepatic circulation, leading to gallstone formation ([@b37-etm-0-0-7291],[@b38-etm-0-0-7291]). Various mechanisms have been consequently speculated, including *Helicobacter* spp. in the gallstone nuclei, systemic immune response alteration and modulation of enterohepatic cycling of conjugated bile acids ([@b39-etm-0-0-7291]). Infection with *Helicobacter pylori* is positively associated with high low-density lipoprotein cholesterol (LDL-C), low HDL-C and CVD ([@b40-etm-0-0-7291]). Patients that are *Helicobacter* seropositive with the TT genotype of the polymorphic gene adiponectin receptor 2 rs1044471 constitute a risk group of cardiovascular event formation ([@b41-etm-0-0-7291]). In light of these findings, therapies targeting the gut microbiota present novel opportunities for CVD and GD treatment.

Genetic studies have highlighted several single nucleotide polymorphisms that may characterize patients with a high risk for GD and CVD. Several genes in the cholesterol metabolism pathway serve an important role in lipid biosynthesis, metabolism and transport. Variants of these genes may significantly influence plasma total cholesterol and LDL-C levels, and in turn affect the pathogenesis of GD and CVD. For example, the ATP-binding cassette G8 (ABCG8) gene is expressed exclusively in the liver and intestine, and forms heterodimers to regulate the efflux of sterols into the intestinal lumen and controls the hepatic secretion of sterols into the bile. The ABCG8 D19H variant is associated with plasma total cholesterol and LDL-C levels ([@b42-etm-0-0-7291],[@b43-etm-0-0-7291]), and confers risk for CVD and GD. Previous research has revealed that the presence of the e4 allele of apolipoprotein E gene is a risk factor for CVD and GD, and is associated with significantly higher levels of LDL-C, TC and non-HDL-C ([@b44-etm-0-0-7291],[@b45-etm-0-0-7291]).

Notably, this meta-analysis has several limitations. First, heterogeneity was revealed through the pooled analysis among studies. The present meta-analysis is unlikely to fully account for heterogeneity, even with the explanation of certain clues from the subgroup analysis. Therefore, the results of the meta-analysis must be interpreted with caution. Because of the potential heterogeneity in age, sex, follow-up, geographical region and study design, it was assumed that the estimated true effect would vary between study designs, in addition to the years of follow-up. Heterogeneity was accounted for by using combined results of the eligible studies with the random-effect model. Although the random-effect approach provides some heterogeneity allowance beyond sampling error or a limited influence, it does not necessarily rule out the heterogeneity effect. Second, although Egger\'s test suggested no publication bias for the HR; the inverted funnel plots of the HR were not symmetrical. The source of publication bias may originate from the nonrandomized studies, including prospective cohort and retrospective cohorts. Finally, unpublished data/studies that may have met the inclusion criteria were not included. In addition, potential biases may have been produced in the present meta-analysis.

In conclusion, the present study demonstrated that the presence of GD was associated with an increased risk of CVD incidence and prevalence. Further studies are required with more randomized controlled trials to elucidate the molecular mechanisms underlying the association between these two diseases, and whether preventive therapies would prevent the progression of CVD in patients with GD.
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###### 

Characteristics of the included studies summarized in the meta-analysis.

  Author, year               Group                  Sex/age (years)   Gallstone patients and control with/without cardio-cerebrovascular diseases   OR/HR (95% CI)        Followed-up (years)   Study design                                Region               Outcome   Confounder adjusted                         Quality assessment (newcastle-ottawa scale)   (Refs.)
  -------------------------- ---------------------- ----------------- ----------------------------------------------------------------------------- --------------------- --------------------- ------------------------------------------- -------------------- --------- ------------------------------------------- --------------------------------------------- -----------------------
  Wang *et al*, 2017         Whole cohort           51.7              A:192, B:215, T1:407, C:1851, D:3953, T2:5804                                 OR:1.9 (1.55,2.33)    3                     Prospective cohort                          Taiwan               AS        33                                          7                                             ([@b15-etm-0-0-7291])
  Zheng *et al*, 2016        Independent cohort 1   Female/48.6       T1:8796, T2:103724                                                            HR:1.15 (1.1,1.21)    30                    Retrospective cohort                        USA                  CHD       5,9,11,12,13,19,20,22,24,25,27,28           8                                             ([@b8-etm-0-0-7291])
                             Independent cohort 2   Female/36.4       T1:5227, T2:107692                                                            HR:1.33 (1.17,1.51)   22                                                                USA                  CHD       5,9,11,12,13,19,20,22,24,25,27,28           8                                             ([@b8-etm-0-0-7291])
                             Independent cohort 3   Male/60.1         T1:1449, T2:42254                                                             HR:1.11 (1.04,1.2)    24                                                                USA                  CHD       5,9,11,12,13,19,20,22,24,25,27,28           8                                             ([@b8-etm-0-0-7291])
  Lv *et al*, 2015           Whole cohort             30--79          A:1942, B:26403, T1:28345, C:23017, D:436011, T2:459028                       HR:1.23 (1.17,1.28)   7.2                   Prospective cohort                          China                IHD       1,2,7,12,14,15,16,17,19,21,22,24,29,31,32   8                                             ([@b9-etm-0-0-7291])
                             Sex subgroup 1         Male/30--79       T1:7374, T2:191918                                                            HR:1.11 (1.02,1.22)                                                                     China                IHD       1,2,7,12,14,15,16,17,19,21,22,24,29,31,32   8                                             ([@b9-etm-0-0-7291])
                             Sex subgroup 2         Female/30--79     T1:21029, T2:267052                                                           HR:1.27 (1.2,1.34)                                                                      China                IHD       1,2,7,12,14,15,16,17,19,21,22,24,29,31,32   8                                             ([@b9-etm-0-0-7291])
  Wei *et al*, 2014          Whole cohort           NA                A:12234, B:123278, T1:135512, C:20680, D:250344, T2:271024                    HR:1.29 (1.26,1.32)   8                     Retrospective cohort Retrospective cohort   Taiwan               Stroke    1,11,17,19                                  7                                             ([@b16-etm-0-0-7291])
                             Disease subgroup 1     NA                A:10500, B:125012, T1:135512, C:17748, D:253276, T2:271024                    HR:1.33 (1.25,1.41)                                                                     Taiwan               HS        1,11,17,19                                  7                                             ([@b16-etm-0-0-7291])
                             Disease subgroup 2     NA                A:1734, B:133778, T1:135512, C:2932, D:268092, T2:271024                      HR:1.28 (1.25,1.31)                                                                     Taiwan               IS        1,11,17,19                                  7                                             ([@b16-etm-0-0-7291])
                             Sex subgroup 1         Male              T1:66792, T2:133584                                                           HR:1.39 (1.28,1.51)                                                                     Taiwan               Stroke    1,17,18,19                                  7                                             ([@b16-etm-0-0-7291])
                             Sex subgroup 2         Female            T1:68720, T2:137440                                                           HR:1.25 (1.14,1.37)                                                                     Taiwan               Stroke    1,17,18,19                                  7                                             ([@b16-etm-0-0-7291])
                             Age subgroup 1         \<45              T1:30655, T2:61310                                                            HR:2.41 (1.93,3.01)                                                                     Taiwan               Stroke    1,17,18,19                                  7                                             ([@b16-etm-0-0-7291])
                             Age subgroup 2           45--64          T1:50510, T2:101020                                                           HR:1.46 (1.31,1.62)                                                                     Taiwan               Stroke    1,17,18,19                                  7                                             ([@b16-etm-0-0-7291])
                             Age subgroup 3           ≥65             T1:54347, T2:108694                                                           HR:1.12 (1.04,1.21)                                                                     Taiwan               Stroke    1,17,18,19                                  7                                             ([@b16-etm-0-0-7291])
  Lee *et al*, 2013          Whole cohort           60.9              A:126, B:252, T1:378                                                          HR:2.11 (1.14,3.9)    3.9                   Retrospective cohort                        Korea                CAD       33                                          7                                             ([@b13-etm-0-0-7291])
  Wirth *et al*, 2013        Whole cohort           54.1              A:134, B:4696, T1:4828, C:785, D:40873, T2:41658                              HR:1.09 (0.8,1.5)     8.2                   Prospective cohort                          German               CVD       1,2,7,14,19,24,26,                          8 29,30,32                                    ([@b17-etm-0-0-7291])
  Olaiya *et al*, 2013       Whole cohort             NA              A:935, B:6046, T1:6981, C:2758, D:25166, T2:27924                             HR:1.32 (1.22,1.43)   6                     Retrospective cohort Retrospective cohort   Taiwan               CVD       1,4,17                                      7                                             ([@b14-etm-0-0-7291])
                             Disease subgroup 1     NA                NA                                                                            HR:1.15 (1.01,1.32)                                                                     Taiwan               Stroke    1,4,17                                      7                                             ([@b14-etm-0-0-7291])
                             Disease subgroup 2       NA              NA                                                                            HR:1.42 (1.28,1.58)                                                                     Taiwan               CHD       1,4,17                                      7                                             ([@b14-etm-0-0-7291])
                             Sex subgroup 1         Male              A:425, B:2632, T1:3057, C:1265, D:10963, T2:12228                             HR:1.29 (1.15,1.44)                                                                     Taiwan               CVD       1,2,6,8,9,12,19,23                          7                                             ([@b14-etm-0-0-7291])
                             Sex subgroup 2         Female            A:510, B:3414, T1:3924, C:1493, D:14203, T2:15696                             HR:1.35 (1.22,1.5)                                                                      Taiwan               CVD       1,2,6,8,9,12,19,23                          7                                             ([@b14-etm-0-0-7291])
                             Age subgroup 1         18--40            A:88, B:2057, T1:2145, C:228, D:8352, T2:8580                                 HR:1.42 (1.09,1.84)                                                                     Taiwan               CVD       1,2,6,8,9,11,17,19,23                       7                                             ([@b14-etm-0-0-7291])
                             Age subgroup 2         41--60            A:464, B:2923, T1:3387, C:1273, D:12278, T2:13551                             HR:1.35 (1.21,1.51)                                                                     Taiwan               CVD       1,2,6,8,9,11,17,19,23                       7                                             ([@b14-etm-0-0-7291])
                             Age subgroup 3         \>60              A:383, B:1066, T1:1449, C:1257, D:4536, T2:5793                               HR:1.24 (1.1,1.39)                                                                      Taiwan               CVD       1,2,6,8,9,11,17,19,23                       7                                             ([@b14-etm-0-0-7291])
  Ruhl and Everhart, 2011    Whole cohort           69.5              A:247, B:1771, T1:2018, C:639, D:11571, T2:12210                              HR:1.5 (1.3,1.8)      18                    Prospective cohort                          USA                  CVD       1                                           9                                             ([@b2-etm-0-0-7291])
  Khan *et al*, 2009         Whole cohort           78                A:889, B:1321, T1:2210, C:874, D:1336, T2:2210                                OR:0.97 (0.86,1.90)   10                    Prospective cohort                          South East England   CHD       1,17                                        7                                             ([@b18-etm-0-0-7291])
  Bortnichak *et al*, 1985   Whole cohort             28--62          A:111, B:391, T1:502, C:649, D:3557, T2:4206                                  OR:1.56 (1.24,1.95)   26                    Retrospective cohort                        USA                  CHD       33                                          7                                             ([@b19-etm-0-0-7291])
                             Sex subgroup 1         Female/28--62     A:44, B:278, T1:322, C:189, D:1989, T2:2178                                   OR:1.67 (1.17,2.37)                                                                     USA                  CHD       33                                          7                                             ([@b19-etm-0-0-7291])
                             Sex subgroup 2         Male/28--62       A:67, B:113, T1:180, C:460, D:1568,T2:2028                                    OR:2.02 (1.47,2.78)                                                                     USA                  CHD       33                                          7                                             ([@b19-etm-0-0-7291])

A, gallstone with cardio-cerebrovascular diseases; B, gallstone without cardio-cerebrovascular diseases; T1, gallstone; C, control with cardio-cerebrovascular diseases; D, control without cardio-cerebrovascular diseases; T2, control; CVD, cardiovascular disease; CAD, coronary artery disease; CHD, coronary heart disease; HS, hemorrhagic stroke; IHD, ischemic heart disease; IS, ischemic stroke; NA, not applicable; 1, age; 2, alcohol consumption; 3, alcoholism; 4, all the co-morbid variables as covariates; 5, Alternative Health; 6, anemia; 7, body mass index; 8, chronic liver disease; 9, chronic obstructive pulmonary disease; 10, daily cholesterol intake; 11, daily energy intake; 12, diabetes mellitus; 13, Eating Index Score; 14, education; 15, family history of heart attack; 16, fresh fruits; 17, sex; 18, history of hypertension, diabetes, coronary heart disease, atrial fibrillation and hyperlipidemia; 19, hypertension; 20, hypercholesterolemia; 21, intake of red meat; 22, marital status; 23, peripheral vascular disease; 24, physical activity; 25, post-menopausal hormone replacement; 26, prevalent hypertension and hyperlipidemia; 27, race; 28, regular aspirin use; 29, smoking; 30, study center; 31, vegetables; 32, waist circumference; 33, unadjusted.

###### 

Stratified analyses of the risk of cardiovascular disease among patients with gallstones.

  A, Group 1                                                                                                                    
  ------------------------------ ---------------------- ----------------- ------------- -------------- ------------------------ --------------
  Mean age                                                                                                                      
    \<45                         HR: 1.65               (1.14, 2.40)      3             90.5           \<0.001                  29.85
    ≤60                          Unadjusted OR: 1.47    (1.38, 1.58)      4             0              0.979                    39.23
  Sex                                                                                                                           
    Female                       HR: 1.25               (1.18, 1.34)      5             70.5           0.009                    56.13
  Geographical region                                                                                                           
    Asia                         HR: 1.27               (1.21, 1.32)      5             55.5           0.061                    53.89
    Western                      Unadjusted OR: 1.29    (1.22, 1.37)      4             97.4           \<0.001                  7.08
  Follow-up (year)                                                                                                              
    \<10                         HR: 1.26               (1.21, 1.32)      6             49.8           0.076                    56.30
    \<10                         Unadjusted OR: 1.27    (1.19, 1.34)      3             98.2           \<0.001                  6.23
  Study design                                                                                                                  
    Prospective cohort study     HR: 1.29               (1.10, 1.50)      3             66.7           0.050                    24.48
    Prospective cohort study     Unadjusted OR: 1.35    (1.30, 1.39)      5             96.7           \<0.001                  21.59
  Sample size (gallstone)                                                                                                       
    \>10,000                     Unadjusted OR: 1.24    (1.21, 1.26)      5             96.8           \<0.001                  93.45
                                                                                                                                
  **B, Group 2**                                                                                                                
                                                                                                                                
  **Subgroup**                   **HR/unadjusted OR**   **RR (95% CI)**   **Reports**   **I^2^ (%)**   **P~(heterogeneity)~**   **Weight %**
                                                                                                                                
  Mean age                                                                                                                      
    ≥45                          HR: 1.20               (1.11, 1.30)      5             81.4           \<0.001                  70.15
    \>60                         Unadjusted OR: 1.24    (1.17, 1.30)      3             98.2           \<0.001                  60.77
  Sex                                                                                                                           
    Male                         HR: 1.22               (1.08, 1.37)      4             85.8           \<0.001                  43.87
  Geographical region                                                                                                           
    Western                      HR: 1.22               (1.11, 1.34)      5             74.4           0.004                    46.11
    Asia                         Unadjusted OR: 1.23    (1.20, 1.25)      4             94.3           \<0.001                  92.92
  Follow-up (year)                                                                                                              
    ≥10                          HR: 1.23               (1.11, 1.36)      4             80.5           0.001                    43.70
    ≥10                          Unadjusted OR: 1.23    (1.21, 1.25)      5             92.9           \<0.001                  93.77
  Study design                                                                                                                  
    Retrospective cohort study   HR: 1.23               (1.15, 1.31)      7             83.5           \<0.001                  75.52
    Retrospective cohort study   Unadjusted OR: 1.20    (1.17, 1.22)      3             88.5           \<0.001                  78.41
  Sample size (gallstone)                                                                                                       
    ≤10,000                      Unadjusted OR: 1.15    (1.09, 1.22)      3             94.6           \<0.001                  6.55

HR, hazard ratio; OR, odds ratio; CI, confidence interval; RR, relative risk.
